About Oxford Brain Diagnostics Ltd
Oxford Brain Diagnostics is a medical imaging company on a mission to change the way the world thinks about brain health. The company has developed proprietary technology that analyzes the cellular microstructure of the cerebral cortex in ways previously inaccessible through standard MRI scanning. Their flagship CDM® (Cortical Disarray Measurement) technology uses advanced diffusion tensor imaging to detect microscopic changes in brain tissue years before traditional symptoms appear or standard MRI scans show abnormalities. The company serves two primary markets: pharmaceutical and biotech companies conducting clinical trials for neurodegenerative diseases, and clinicians diagnosing and monitoring patients with conditions like Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. Their CDM Insights product, which has received FDA 510(k) clearance and FDA Breakthrough Device Designation, integrates with existing PACS systems to process standard anatomical and diffusion MRI data in a secure cloud environment, delivering comprehensive reports within 12 hours. Oxford Brain Diagnostics' technology enables earlier detection, more accurate differential diagnosis, and precise tracking of disease progression. For pharmaceutical companies, this translates to more targeted and efficient clinical trials with novel biomarkers that can demonstrate drug efficacy. For clinicians, it provides quantitative analysis of brain structures, microstructural changes, cortical thickness, and regional volumes in a single comprehensive report. The company is ISO 13485 and ISO 27001 certified and compliant with GDPR and HIPAA data privacy standards.
Mission & Story
Mission
We are on a mission to change the way the world thinks about brain health
Clinical Focus
Medical conditions and clinical areas addressed by Oxford Brain Diagnostics Ltd.
Who It Serves
Milestones & Awards
Recent Milestones
FDA 510(k) clearance for CDM Insights; FDA Breakthrough Device Designation for CDM®; Partnership with Caladrix for Phase 1b trial in Alzheimer's (January 2025); New Parkinson's research published (April 2025); INmune Bio Phase 2 data using CDM PerpPD+ (December 2025)
Awards & Recognition
FDA Breakthrough Device Designation
Key Partnerships
Company Details
- Founded
- 2018
- Headquarters
- Oxford, England, United Kingdom
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 189 →
A2z Radiology Ai
AI platform that triages urgent abdomen-pelvis CT findings and prioritizes flagged studies in radiology worklists.
Adas3D Medical S.L
11-50 employees
Adas3D Medical develops medical imaging software that extracts key clinical information from cardiac MRI and CT scans for electrophysiologists. The software helps plan, guide, and monitor catheter ablation procedures by visualizing and quantifying fibrotic tissue in the heart.
AEYE Health
11-50 employees
AEYE Health provides FDA-cleared autonomous AI diagnostic screening for diabetic retinopathy and other eye diseases using retinal images. Their point-of-care solution enables primary care physicians to screen and diagnose patients instantly with portable or desktop cameras.
Agfa HealthCare N.V.
AGFA HealthCare provides enterprise imaging platforms that unify medical imaging across specialties. The company delivers PACS, vendor neutral archives, AI-powered workflow orchestration, and cloud-based imaging solutions to hospitals and healthcare systems worldwide.
AI4MedImaging Medical Solutions
AI4MedImaging provides AI-powered medical imaging solutions distributed through aycan Medical Systems in the Americas. Their flagship product, AI4CMR, is software as a medical device (SaMD) that automates the interpretation of cardiac magnetic resonance imaging using artificial intelligence.
Aidence
Aidence, now part of DeepHealth, develops AI-powered clinical applications for radiology and medical imaging. The company specializes in lung nodule detection, classification, and patient management solutions that empower radiologists and physicians in interpreting medical images.
Aidoc
growth · 350 employees
Aidoc empowers health systems to improve patient outcomes and operations with enterprise-grade healthcare AI.
Aikenist Technologies Pvt Ltd
21-100 employees
Aikenist Technologies is a MedTech company specializing in advanced AI-driven solutions for radiology imaging. Their offerings include an FDA-approved AI PACS and RIS with integrated viewer, appointment scheduling, billing modules, and AI tools for stroke, oncology, and neuro detection.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.